/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(98).jpg

Human prostate specific antigen,PSA ELISA Kit

Product#: CS-CSB-E04768h
$580.00
Availability:
Ships in 24 hours

The Ultimate 1-Stop ELISA Marketplace:

60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science

Always Powered by Diagnocine for Precision Research.

 
Made In-USA · ISO 13485 Certified 

Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.  
All-inclusive format covers everything from sample preparation to signal detection.  Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified

One Stop Purchasing but Zero Compromise on Accuracy

Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.  
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version

Low Signal Optimization Reagents

4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.

DCP-PIC100X

Protease Inhibitor Cocktail (100X)

Included with every order
 DCP-SM1AbTBS1X

SigMax 1Ab-TBS

Included with every order
 DCP-UTBS1X

Universal Blocking Buffer

Included with every order
 DCP-SM2AbTBS1X

SigMax 2Ab-TBS

Included with every order

+ the 5th component, matched to your kit's detection method:

DCP-HRPTBS1X

HRPQuench-TBS

Exclusively for HRP-based kits
OR
DCP-ALPTBS1X

ALPQuench-TBS

Exclusively for ALP-based kits

If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.

Key Value Highlights

Universal Compatibility

All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.

1-Stop Convenience

Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.

Enhanced Precision

Designed by scientists for scientists,  all components are engineered to deliver sharper results and an optical signal.

Human ELISA Kit · Cancer

Human prostate specific antigen,PSA ELISA Kit

Sandwich quantitative immunoassay for kallikrein-related peptidase 3 in human serum, plasma, tissue homogenates  available in multiple catalog sizes:

Trial 24T 96T

Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.

Detection Range
0.312-20 ng/mL
Sensitivity
0.078 ng/mL
Assay Time
1-5 hours
Sample Volume
50-100 μL
Product specifications
Target namekallikrein-related peptidase 3
Uniprot No.P07288
SpeciesHomo sapiens (Human)
Sample typesserum, plasma, tissue homogenates
Detection range0.312 ng/mL-20 ng/mL
Sensitivity0.078 ng/mL
Assay time1-5h
Sample loading volume50-100μL
Detection wavelength450 nm
Assay principleSandwich (Quantitative)
Data analysisStandard curve + Curve Expert software
Research areaCancer
Storage condition2-8°C (see protocol for full details)
Shipping condition4 °C
Shelf life6 months
kallikrein-related peptidase 3 serum plasma tissue homogenates Cancer Human ELISA
Lead Time

10 business days

Processing + 3-5 days shipping

Availability

In Stock : USA

Worldwide shipping available

Assay principle
Sample prep
Antibody capture
450 nm detection
Standard curve
Quantification

In this sandwich ELISA, kallikrein-related peptidase 3 in the sample is captured between a pre-coated capture antibody and a detection antibody. Signal intensity is proportional to analyte concentration. Quantification uses a standard curve fitted with Curve Expert software, covering 0.312 ng/mL-20 ng/mL with a minimum detectable dose of 0.078 ng/mL.

For research use only (RUO). Not intended for diagnostic or therapeutic purposes. Validated in human serum, plasma, tissue homogenates matrices only.
Description

The human PSA ELISA Kit is intended to measure human PSA in serum, plasma, or tissue homogenates. This assay uses the bi-antibody sandwich technique and enzyme-substrate chromogenic reaction to quantify human PSA concentration. The intensity of the colored product is positively proportional to the concentration of PSA present in the sample. This human PSA ELISA kit has high specificity and excellent sensitivity.

PSA is a serine protease with chymotrypsin-like enzymatic activity. It is expressed predominantly in the prostate and a subset of proximal renal tubules. It mainly functions to degrade the gel-forming proteins semenogelins I and II in semen after ejaculation. This process causes the seminal clot to liquefy and motile sperm to be released, allowing the spermatozoa to pass through the female reproductive canal. PSA level in semen has been shown to correlate with sperm motility, suggesting that PSA level/activity can affect fertility. PSA is a credentialed imaging and therapy (theranostic) target for the detection and treatment of prostate cancer.

Alternative Names
antigen; prostate-specific ELISA Kit; APS ELISA Kit; Gamma seminoprotein ELISA Kit; Gamma-seminoprotein ELISA Kit; hK3 ELISA Kit; Kallikrein 3 ELISA Kit; Kallikrein related peptidase 3 ELISA Kit; Kallikrein-3 ELISA Kit; KLK 3 ELISA Kit; KLK2A1 ELISA Kit; Klk3 ELISA Kit; KLK3_HUMAN ELISA Kit; P-30 antigen ELISA Kit; P30 antigen ELISA Kit; Prostate-specific antigen ELISA Kit; Psa ELISA Kit; Semenogelase ELISA Kit; Seminin ELISA Kit
Function
Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum.
Gene References into Functions
  1. No significant differences in in KLK3 expression were found between radical prostatectomy-prostate cancer and radical prostatectomy-benign samples. PMID: 26928323
  2. Both the incidence of early-stage prostate cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality. PMID: 27010657
  3. I might also point out that whether a particular surgical procedure did more good than harm at that time was highly dependent on whether it was conducted with good sterile procedure. PSA screening is a contemporary example of this historical lesson PMID: 27010733
  4. For PSA screening to be cost-effective, it needs to be used conservatively and ideally in combination with a conservative management approach for low-risk disease PMID: 27010943
  5. Studies indicate that the prostate health index (phi) is a biomarker panel that includes free prostate-specific antigen (PSA), total PSA, and [-2]proPSA. PMID: 27023445
  6. novel urinary gene expression signature that may be the least invasive of available options by not requiring a digital rectal examination or phlebotomy as a reflex test in men for whom PSA testing raises the suspicion of prostate cancer PMID: 27031887
  7. Results show that urinary PSA glycoforms are able to discriminate prostate cancer from protastatic hyperplasia with higher sensitivity and specificity for prostate cancer than those of the serum PSA marker. PMID: 27065039
  8. The prostate-specific antigen density (PSAD) cutoff level generated for Nigerian men in this study is 0.04 which is relatively different from international consensus. This PSAD cutoff level has a positive correlation with histology and could detect patients with prostate cancer who have "grey zone PSA." PMID: 27356753
  9. Higher miR-139-5p expression in prostate cancer patients was observed to be associated with certain clinicopathological parameters, including PSA greater than 20ng/ml, pathological tumor stage, and Gleason score. PMID: 27562849
  10. Circulating total PSA levels were strongly associated to leukocyte telomere length in a national sample of men without prostate cancer. PMID: 27566127
  11. Data suggest that occurrence of PSA failure was associated with increased risk of all-cause mortality (ACM) only in men with no or minimal, but not moderate-to-severe, comorbidity. PMID: 27601545
  12. A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening. PMID: 27630329
  13. Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course. PMID: 27741512
  14. The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients PMID: 27805011
  15. Data indicate that prostate specific antigen (PSA) is a negative predictive biomarker for local recurrence during follow-up. PMID: 27834929
  16. Extended follow-up of the PLCO trial over a median of 15 years continues to indicate no reduction in prostate cancer mortality for the intervention arm versus the control arm. Because of the high rate of control-arm PSA testing, this finding can be viewed as showing no benefit of organized screening versus opportunistic screening PMID: 27911486
  17. The combined efficacies of whole-body magnetic resonance imaging, bone scintigraphy and PSA levels were desired in identifying prostate cancer lesions and prognosis. PMID: 27941343
  18. Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer. PMID: 28039477
  19. Older men who underwent no PSA testing or incomplete testing were significantly more likely to be diagnosed with high-risk prostate cancer than those who were previously screened. It is reasonable to consider screening in healthy older men likely to benefit from early detection and treatment. PMID: 28045113
  20. end-of-radiation PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation. PMID: 28094250
  21. Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure. PMID: 28117382
  22. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression. PMID: 28117385
  23. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. PMID: 28139693
  24. Promoter methylation of MCAM, ERalpha and ERbeta have a potential to be utilized as biomarker for the early detection of prostate cancer (PC) as their sensitivity and specificity seem to be better than serum PSA. PMID: 28147335
  25. Data show that forkhead box M1 protein (FOXM1) directly binds to the FHK binding motifs in the prostate specific antigen (PSA) promoter/enhancer regions. PMID: 28199985
  26. The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively. PMID: 28213364
  27. TC genotype of rs1058205 lower in prostate cancer group than in control group; TT genotype associated with prostate cancer PMID: 28272245
  28. the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH PMID: 28300542
  29. this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians. PMID: 28430620
  30. Data suggest no influence of chronic periodontitis treatment on PSA levels in asymptomatic men. PMID: 28551659
  31. Study suggests that the prognostic value of PSA declines in heavily treated patients receiving enzalutamide PMID: 28614217
  32. Microenvironmental acidity determines qualitatively and quantitatively the release of extracellular vesicles by malignant prostate tumors. This leads to the spill-over of nanovesicles into the peripheral blood of prostate cancer patients, where the levels of tumor biomarkers expressed by exosomes, such as PSA-exosomes, may represent a novel, non-invasive diagnostic tool. PMID: 28694142
  33. Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed PMID: 29156407
  34. The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits) PMID: 29172142
  35. he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis. PMID: 29175217
  36. PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer. PMID: 29259293
  37. ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors. PMID: 29414091
  38. PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients. PMID: 29714659
  39. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies. PMID: 29734838
  40. Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia PMID: 29795141
++ 10 more research findings link this target to additional biology. Showing the 40 most recent — the full set appears on the complete datasheet.
Subcellular Location
Secreted.
Protein Families
Peptidase S1 family, Kallikrein subfamily
Database Links

HGNC: 6364

OMIM: 176820

KEGG: hsa:354

STRING: 9606.ENSP00000314151

UniGene: Hs.171995

Precision

Human prostate specific antigen,PSA ELISA Kit

Linearity

 

Satisfaction
Quality Rating
Value Rating
Style Rating
X